Thomas Michael Shiju1, Viswanathan Mohan2, Muthuswamy Balasubramanyam2, Pragasam Viswanathan3. 1. Renal Research Lab, Centre for Bio medical Research, School of Bio Sciences and Technology, VIT University, Vellore 632 014, India. 2. Department of Cell and Molecular Biology, Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialties Centre, Gopalapuram, Chennai, India. 3. Renal Research Lab, Centre for Bio medical Research, School of Bio Sciences and Technology, VIT University, Vellore 632 014, India. Electronic address: pragasam.v@vit.ac.in.
Abstract
AIMS: This study was designed to analyze the level of soluble CD36 (sCD36) in both plasma and urine of type 2 diabetic patients with and without microalbuminuria/macroalbuminuria. METHODS: Study subjects (n=20 each) comprised of those with normal glucose tolerance, type 2 diabetes (T2DM) with normoalbuminiria, T2DM with microalbuminuria and T2DM with macroalbuminuria. The biochemical parameters were analyzed using auto-analyzer, and the level of sCD36 was estimated using an in-house Sandwich ELISA. RESULTS: The presence of sCD36 has been identified for the first time in the urine sample. Significant increase in the level of sCD36 was observed in both plasma and urine of diabetic patients with microalbuminuria (P<0.01) and macroalbuminuria (P<0.001). Positive correlation of sCD36 with the kidney markers such as urea, creatinine and eGFR confirmed the association of sCD36 with kidney damage in diabetic patients. Microalbuminuria, which is clinically used as a biomarker for nephropathy showed a strong positive correlation with urine sCD36 (r=0.642; P<0.001) and plasma sCD36 (r=0.498; P<0.001) in Pearson correlation analysis, which was further substantiated in stepwise multiple regression analysis. CONCLUSIONS: Our study implies a plausible prognostic/adjuvant biomarker role of soluble CD36 for diabetic nephropathy.
AIMS: This study was designed to analyze the level of soluble CD36 (sCD36) in both plasma and urine of type 2 diabeticpatients with and without microalbuminuria/macroalbuminuria. METHODS: Study subjects (n=20 each) comprised of those with normal glucose tolerance, type 2 diabetes (T2DM) with normoalbuminiria, T2DM with microalbuminuria and T2DM with macroalbuminuria. The biochemical parameters were analyzed using auto-analyzer, and the level of sCD36 was estimated using an in-house Sandwich ELISA. RESULTS: The presence of sCD36 has been identified for the first time in the urine sample. Significant increase in the level of sCD36 was observed in both plasma and urine of diabeticpatients with microalbuminuria (P<0.01) and macroalbuminuria (P<0.001). Positive correlation of sCD36 with the kidney markers such as urea, creatinine and eGFR confirmed the association of sCD36 with kidney damage in diabeticpatients. Microalbuminuria, which is clinically used as a biomarker for nephropathy showed a strong positive correlation with urine sCD36 (r=0.642; P<0.001) and plasma sCD36 (r=0.498; P<0.001) in Pearson correlation analysis, which was further substantiated in stepwise multiple regression analysis. CONCLUSIONS: Our study implies a plausible prognostic/adjuvant biomarker role of soluble CD36 for diabetic nephropathy.
Authors: Sudipta Biswas; Detao Gao; Jessica B Altemus; Umar R Rekhi; Ellen Chang; Maria Febbraio; Tatiana V Byzova; Eugene A Podrez Journal: Free Radic Biol Med Date: 2021-03-26 Impact factor: 7.376
Authors: Ya Li; Weiguo Ma; Chuanqing Xie; Min Zhang; Xiaohong Yin; Fenfen Wang; Jie Xu; Bingyin Shi Journal: Medicine (Baltimore) Date: 2016-11 Impact factor: 1.889
Authors: Nathan Lawlor; Joshy George; Mohan Bolisetty; Romy Kursawe; Lili Sun; V Sivakamasundari; Ina Kycia; Paul Robson; Michael L Stitzel Journal: Genome Res Date: 2016-11-18 Impact factor: 9.043
Authors: Ho Jin Kim; Jun Sung Moon; Il Rae Park; Joong Hee Kim; Ji Sung Yoon; Kyu Chang Won; Hyoung Woo Lee Journal: Endocrinol Metab (Seoul) Date: 2017-09